Gabriele Matschiner

This inventor holds 21 USPTO granted patents and 8 published patent applications, plus 5 CIPO patents and 9 EPO patents. Top assignees: Pieris Pharmaceuticals Gmbh, Pieris Ag, Astrazeneca Ab. Active years: 2011-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gabriele Matschiner. Retrieved from https://idiyas.com/inventor/gabriele-matschiner

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21 (Patent Applications = 8)

% Patents Active = 66.7

CIPO Patents = 5 (Patent Applications = 8)

EPO Patents = 9 (Patent Applications = 20)

Average Co-Inventor Count = 6.0

ph-index = 6

Forward Citations = 118(Granted Patents)

Location History:

München, DE (2011)
Munich, DE (2015 - 2023)

Company Filing History:

12 out of 37

Pieris Pharmaceuticals Gmbh

Daiichi Sankyo Company, Limited

patents

5. 1 out of 834,453

Other

patents

where one patent can have more than one assignee

Years Active: 2011-2023

Loading Chart...

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11827681 - Muteins of human lipocalin 2 (Lcn2, hNGAL) with affinity for a given target (2023-11-28),

2. 11034737 - Proteins specific for calcitonin gene-related peptide (2021-06-15),

3. 10927154 - Multi-specific polypeptide useful for localized tumor immunomodulation (2021-02-23),

4. 10898545 - Tear lipocalin muteins binding IL-4 r alpha (2021-01-26),

5. 10787491 - Nucleic acid molecules encoding muteins of human lipocalin 2 with affinity for glypican-3 (GPC3) (2020-09-29),

6. 10618941 - Muteins of human lipocalin 2 (Lcn2,hNGAL) with affinity for a given target (2020-04-14),

7. 10526384 - Interleukin-17A-specific and interleukin-23-specific binding polypeptides and uses thereof (2020-01-07),

8. 10400016 - Proteins specific for calcitonin gene-related peptide (2019-09-03),

9. 10273275 - Muteins of human lipocalin 2 with affinity for glypican-3 (GPC3) and methods of use thereof (2019-04-30),

10. 10232014 - Tear lipocalin muteins binding IL-4 R alpha (2019-03-19),

11. 9751920 - Muteins with tear lipocalin having affinity to human c-met receptor tyrosine kinase and methods for obtaining the same (2017-09-05),

12. 9687524 - Tear lipocalin muteins binding IL-4 R alpha (2017-06-27),

13. 9598476 - Nucleic acid molecules encoding muteins of human tear lipocalin which bind PCSK9 (2017-03-21),

14. 9549968 - Muteins of human lipocalin 2 (LcnC,hNGAL) with affinity for a given target (2017-01-24),

15. 9260492 - Muteins of human lipocalin 2 with affinity for glypican-3 (GPC-3) (2016-02-16),

Title: Gabriele Matschiner: Innovator in Biomedical Patents

Introduction: Gabriele Matschiner, a prolific inventor based in Munich, Germany, holds an impressive portfolio of 21 patents. His groundbreaking work in the field of biomedical research has significantly impacted therapeutic developments.

Latest Patents: Among his recent inventions, Matschiner has developed muteins of human lipocalin 2 (Lcn2, hNGAL) that exhibit affinity for specific targets. This innovative library enables the generation of novel muteins that have applications in binding and depleting pathological forms of natural biomolecules, such as the amyloid beta peptide implicated in Alzheimer's disease. Furthermore, he has created muteins that target the fibronectin extra-domain B associated with tumor neovasculature, showcasing potential in cancer therapies. Additionally, his work includes proteins specific for calcitonin gene-related peptide (CGRP), which may hold promise for pharmaceutical applications, especially in treating migraines. The comprehensive nature of his patents extends to methods for producing these muteins and corresponding nucleic acid molecules.

Career Highlights: Gabriele Matschiner has made significant contributions to the life sciences sector, particularly through his work at Pieris Pharmaceuticals GmbH and Pieris AG. His expertise in molecular biology and biochemistry has positioned him as a key player in the development of novel therapeutic approaches. His ability to innovate and create impactful patents has made a lasting mark in the industry.

Collaborations: Throughout his career, Matschiner has collaborated with notable professionals such as Andreas Hohlbaum and Martin Huelsmeyer. These partnerships have enriched his research endeavors and have contributed to the successful progression of his inventions.

Conclusion: Gabriele Matschiner continues to be an influential figure in the realm of biomedical patents. His dedication to advancing scientific knowledge and developing practical applications for his inventions demonstrates the essence of innovation. As he forges ahead, Matschiner's work holds significant promise for addressing some of today's most challenging medical conditions.

Profile summary based on public USPTO records.